You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: AGAVE BIOSYSTEMS INC. Topic: CBD08103
Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs while providing protection against CB ...SBIR Phase II 2009 Department of DefenseOffice for Chemical and Biological Defense
SBC: Zymeron Corporation Topic: CBD181004
Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
SBC: SensoDX II, LLC Topic: A16AT008
The synthetic opioids fentanyl and carfentanil pose an imminent national security threat, given the ease with which they can be obtained, their low lethal doses, and their potential for weaponized use. The purpose of this agreement is to adapt SensoDx’s high-performance miniaturized diagnostics platform based on a programmable bio-nano-chip, with embedded artificial intelligence, to enable U.S. ...SBIR Phase II 2019 Department of DefenseOffice for Chemical and Biological Defense